Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study

Pierfrancesco Bassi, Marco Racioppi, Daniele D'Agostino, Giuseppe Palermo, Andrea Volpe, D Renier, S Franchini, A Rosato

Research output: Contribution to journalArticle

Abstract

Carcinoma in situ represents high grade anaplasia of the bladder mucosa. Intravesical immunotherapy with bacillus Calmette-Guérin is the gold standard treatment for patients with carcinoma in situ. Patients with carcinoma in situ refractory to bacillus Calmette-Guérin are candidates for major surgery such as radical cystectomy. We identified the maximum tolerated dose and the recommended dose, and evaluated the safety profile of paclitaxel-hyaluronic acid bioconjugate given by intravesical instillation to patients with carcinoma in situ refractory to bacillus Calmette-Guérin.
Original languageEnglish
Pages (from-to)445-449
Number of pages5
JournalTHE JOURNAL OF UROLOGY
Volume185
DOIs
Publication statusPublished - 2011

Keywords

  • Adjuvants, Immunologic
  • Administration, Intravesical
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • BCG Vaccine
  • Biopsy, Needle
  • Carcinoma in Situ
  • Cystoscopy
  • Disease-Free Survival
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Resistance, Neoplasm
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Humans
  • Hyaluronic Acid
  • Italy
  • Male
  • Maximum Tolerated Dose
  • Middle Aged
  • Neoplasm Staging
  • Paclitaxel
  • Patient Selection
  • Survival Analysis
  • Treatment Outcome
  • Urinary Bladder Neoplasms
  • Young Adult

Fingerprint

Dive into the research topics of 'Paclitaxel-hyaluronic acid for intravesical therapy of bacillus Calmette-Guérin refractory carcinoma in situ of the bladder: results of a phase I study'. Together they form a unique fingerprint.

Cite this